Cell Membrane News and Research

RSS

Study paints clear picture of how a protein that calms brain activity works

As the body goes about its daily business, molecules called neurotransmitters control the level of electrical activity within the brain.

17 Jun 2020

Researchers use cellular nanosponges to soak up SARS-CoV-2

Scientists are working overtime to find an effective treatment for COVID-19, the illness caused by the new coronavirus, SARS-CoV-2.

17 Jun 2020

Nanosponges could attack and neutralize SARS-COV-2 virus

Nanoparticles cloaked in human lung cell membranes and human immune cell membranes can attract and neutralize the SARS-CoV-2 virus in cell culture, causing the virus to lose its ability to hijack host cells and reproduce.

17 Jun 2020

SARS-CoV-2 mutation reduces S1 shedding, increases infective potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans. SARS-CoV-2 emerged in the last month of 2019 in Wuhan, China, sparking off the ongoing COVID-19 pandemic. This virus enters the host cells through receptor binding and membrane fusion between the viral and host cell membrane.

16 Jun 2020

Newfound knowledge may prove valuable to understand human nerve cells

Researchers discover what's behind nature's perhaps largest erection - which is not that big PLANT BIOLOGY.

16 Jun 2020

Glycans "lock and load" the SARS-CoV-2 spike protein for infection

A new study by scientists from the University of California San Diego, USA and Maynooth University, Ireland and published on the preprint server bioRxiv* in June 2020 reports preliminary results showing that the spike protein of the SARS-CoV-2, as well as its glycan coat, has “hitherto unseen functional and structural” properties. These may be useful in designing novel therapeutics to target this molecule.

14 Jun 2020

Steroidal drugs subvert SARS-CoV-2 interaction with ACE2 receptors

A new study by Italian researchers and published online on the preprint server bioRxiv* in June 2020 reports the ability of several existing steroidal drugs to reduce the binding of the SARS-CoV-2 to the ACE2 receptor. This could help define newer strategies using viral entry blockers to reduce viral load.

14 Jun 2020

Remdesivir prevents replication of SARS-CoV-2 in human intestinal organoids

A new German study published on the preprint server bioRxiv* in June 2020 shows that the drug remdesivir can reduce the replication of SARS-CoV-2 in human intestinal organoids.

14 Jun 2020

NIAID and Moderna scientists describe SARS-CoV-2 vaccine development

Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.

14 Jun 2020

Race-related differences in genetic determinants of COVID-19 severity

Researchers at the University of Iowa have identified differences in gene expression levels between African Americans and European Americans that may explain the disproportionately higher rates of coronavirus disease 2019 (COVID-19) cases and related deaths among African Americans.

11 Jun 2020

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

The coronavirus pandemic is actively spreading across the globe, with millions of people infected. Amid the global health crisis, scientists race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 Jun 2020

Metabolic diseases alter ACE2 expression and increase COVID-19 severity

A new study published on the preprint server medRxiv in June 2020 reports that one mechanism for this variable severity is the differential expression of the ACE2 receptor in various metabolic conditions, thereby facilitating viral entry into the host cells.

9 Jun 2020

Designing a prototype spike protein vaccine for SARS-CoV-2

A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.

4 Jun 2020

Researchers decipher deadly bacterial infection in pigs

The Clostridium perfringens bacterium is part of the large Clostridium genus which can cause various fatal illnesses in animals and humans.

4 Jun 2020

A remote optical control for neural cells

A team led by researchers at Carnegie Mellon University has created a new technology that enhances scientists' ability to communicate with neural cells using light.

1 Jun 2020

New MRI technique to improve tumor diagnosis

Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it is critical for overall treatment success and saving patients' lives. DWI may be used to detect a malignancy in various tissues and organs.

1 Jun 2020

Origin of SARS-CoV-2 virus well-suited to jump from animals to humans

A team of scientists studying the origin of SARS-CoV-2, the virus that has caused the COVID-19 pandemic, found that it was especially well-suited to jump from animals to humans by shapeshifting as it gained the ability to infect human cells.

30 May 2020

Toshiba and Shinshu University jointly develop a 'tumor-tropic liposome technology' for gene therapy

Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a “tumor-tropic liposome technology” for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.

30 May 2020

Study solves the longstanding mystery of anesthesia

Surgery would be inconceivable without general anesthesia, so it may come as a surprise that despite its 175-year history of medical use, doctors and scientists have been unable to explain how anesthetics temporarily render patients unconscious.

30 May 2020

How comorbidities affect SARS-CoV-2 viral entry

Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.

28 May 2020